Sanofi Poised To File Isatuximab In Multiple Myeloma, Going Up Against J&J's Darzalex
Isatuximab could be the next building block in Sanofi's ambitions to rebuild in oncology. The CD38-targeting antibody extended PFS in relapsed/refractory multiple myeloma in combination with Celgene's Pomalyst and dexamethasone.
You may also be interested in...
The anti-CD38 antibody will face an entrenched rival, J&J's Darzalex, for multiple myeloma.
The UK scheme allows patients with early access to promising new unlicensed medicines when there is a clear unmet medical need.
The tireless pace of change in hemato-oncology was showcased in Orlando.